Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)

Trial Profile

Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Oropharyngeal cancer; Squamous cell cancer
  • Focus Pharmacodynamics
  • Acronyms CIAO
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 1 Jul 2021 to 1 Jul 2020.
    • 31 Aug 2018 Biomarkers information updated
    • 19 Mar 2018 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top